Clinical Trial Update: Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CD8 PET imaging as a biomarker of immune response to stereotactic body radiation therapy in patients with metastatic solid tum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Snippet

Sponsor: City of Hope Medical Center | Conditions: Metastatic Malignant Solid Neoplasm, Lymphoma | Phase 1 | Status: RECRUITING